Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Titrated atorvastatin versus fixed-dose atorvastatin after NSTEMI
ACTRN12625000608460Phase 3Not yet recruiting
- Sponsor
- Sunshine Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atorvastatin in Non-ST-segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by Sunshine Hospital. Primary endpoint: Change in lipid levels from baseline to 6 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on ACTRN12625000608460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000608460.